Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
November 08, 2021 08:00 ET
|
Scopus BioPharma Inc.
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”) today announced that, on November 5, 2021, its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) was...
Scopus BioPharma Announces Adjournment of Annual Meeting of Stockholders
October 08, 2021 17:30 ET
|
Scopus BioPharma Inc.
NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
Scopus BioPharma to Present at the LD Micro Main Event
October 05, 2021 08:45 ET
|
Scopus BioPharma Inc.
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th...
Scopus BioPharma Retaining Counsel to Investigate Unusual Market Activity
October 01, 2021 16:30 ET
|
Scopus BioPharma Inc.
NEW YORK, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company, announced today that it is retaining Boies Schiller Flexner LLP to...
Scopus BioPharma to Present at MicroCap Rodeo’s Fall Harvest Best Ideas Conference
October 01, 2021 07:00 ET
|
Scopus BioPharma Inc.
Scopus to present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology Presentation to include a discussion of preclinical data released at the 17th...
Scopus BioPharma's Subsidiary — Duet Therapeutics — Announces Release of Preclinical Data Being Presented at 17th Annual Meeting of the Oligonucleotide Therapeutics Society
September 29, 2021 08:30 ET
|
Scopus BioPharma Inc.
Data from two different studies benchmark Duet’s proprietary bifunctional oligonucleotides against immune checkpoint inhibitors (“Checkpoint Inhibitors”) in lymphoma and prostate tumor models in mice ...
Scopus BioPharma’s Subsidiary Duet Therapeutics Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
September 28, 2021 09:15 ET
|
Scopus BioPharma Inc.
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
Scopus BioPharma’s Subsidiary — Duet Therapeutics — Set to Release Scientific Data During the 17th Annual Meeting of the Oligonucleotide Therapeutics Society
September 28, 2021 06:30 ET
|
Scopus BioPharma Inc.
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
Scopus BioPharma to Adjourn 2021 Annual Meeting of Stockholders
September 28, 2021 06:00 ET
|
Scopus BioPharma Inc.
NEW YORK, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...
Scopus BioPharma to Present at the Benzinga Healthcare Small Cap Conference
September 23, 2021 08:30 ET
|
Scopus BioPharma Inc.
NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (Nasdaq: “SCPS”), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with...